|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910973020903321 |
|
|
Autore |
De Messias-Reason Iara |
|
|
Titolo |
Mannose-binding lectin in the innate immune system / / Iara de Messias-Reason and Angelica B.W. Boldt |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Hauppauge, N.Y., : Nova Biomedical Books, 2009 |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[1st ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (99 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Lectins |
Natural immunity |
Mannose |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Intro -- MANNOSE-BINDING LECTIN INTHE INNATE IMMUNE SYSTEM -- MANNOSE-BINDING LECTIN INTHE INNATE IMMUNE SYSTEM -- CONTENTS -- PREFACE -- INTRODUCTION -- 1. MANNOSE BINDING LECTIN (MBL)CHARACTERISTICS -- 1a. MBL2 Gene and Protein Structure -- 1b. MBL2 Transcription and Translation -- 2. MBL FUNCTIONS -- 2a. Activation of Complement -- 2b. Opsonophagocytosis -- 2c. Modulation of Inflamation -- 2d. Recognition of Altered Self and Apoptosis -- 2e. Other MBL Functions -- 3. MBL2 GENE POLYMORPHISM -- 3a. MBL2 Variants and Allelic Haplotypes -- 3b. Worldwide Distribution of MBL2 Haplotypes -- MBL2 ASSOCIATION WITH DISEASES -- 1. POSITIVE ASSOCIATION OF MBL DEFICIENCYWITH DISEASES -- 1a. Otitis Media and other Pediatric Infections -- 1b. Meningitis -- 1c. Mycoplasma Infection -- 1d. Emergent Viral Infection -- 1e. Fungal Infections -- 1f. Malaria -- 1g. Neutropenia -- 1h. Hepatitis B -- 1i. HIV Infection -- 1j. Cystic Fibrosis -- 1k. Systemic Inflammatory Response Syndrome -- 1l. Cardiovascular Diseases -- 1m. Systemic Lupus Erythematosus -- 1n. Gastrointestinal Diseases -- 2. NEGATIVE ASSOCIATION OF MBL DEFICIENCYWITH DISEASES -- 2a. Leprosy -- 2b. Tuberculosis -- 2c. Leishmaniasis -- 2d. Hepatitis C -- 2e. Rheumatic Heart Disease -- 2f. Rheumatoid Arthritis -- 2g. Ischemia/Reperfusion Injury -- 2h. Other Diseases -- 3. MBL AND HETEROZYGOTE ADVANTAGE -- 4. MBL THERAPY -- CONCLUSION -- |
|
|
|
|